menu
    • menu
    [{"orgOrder":0,"company":"Imagine Pharma","sponsor":"Lygenesis","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Imagine Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imagine Pharma \/ Imagine Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Imagine Pharma \/ Imagine Pharma"},{"orgOrder":0,"company":"Imagine Pharma","sponsor":"IP Investors LLC","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"IMG-1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Imagine Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Imagine Pharma \/ IP Investors LLC","highestDevelopmentStatusID":"6","companyTruncated":"Imagine Pharma \/ IP Investors LLC"}]

    Find Clinical Drug Pipeline Developments & Deals by Imagine Pharma

    Menu

    Imagine Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Imagine Pharma

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Imagine Pharma

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Recipient : Lygenesis

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            LyGenesis and Imagine Pharma Announce Joint Research Collaboration to Develop Novel Cell Therapies for Patient...

                            Details : The research collaboration will leverage Imagine Pharma’s Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) and LyGenesis’ allogeneic cell therapy platform to develop therapies for type 1 diabetes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 04, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Recipient : Lygenesis

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Imagine Pharma

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed

                            Imagine Pharma

                            U.S.A arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IMG-1

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : IP Investors LLC

                            Deal Size : $32.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Imagine Pharma Secures $32.5M Series A for Continued Development of its Novel IMG-1 Polypeptide and Associated...

                            Details : The net proceeds will be used to advance the company's priority programs in regenerative medicine, oral delivery, and therapeutics and for the continued development of its novel IMG-1 polypeptide.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 31, 2023

                            Lead Product(s) : IMG-1

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : IP Investors LLC

                            Deal Size : $32.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth